Core Viewpoint - Ying Tai Medical (01501) has entered into a subscription agreement with Kunbo Medical, agreeing to issue a total of 91,093,613 subscription shares at a price of HKD 3.11 per share, totaling HKD 283,301,136.43, subject to the terms and conditions of the agreement [1] Group 1 - The subscription will result in Ying Tai Medical holding approximately 17.24% of Kunbo Medical's issued shares as of the announcement date, and approximately 14.38% of the expanded issued shares post-transaction [1] - The financial performance of Kunbo Medical will not be consolidated into Ying Tai Medical's accounts [1] - The subscription is aimed at expanding Ying Tai Medical's strategic layout in the non-vascular interventional field, leveraging Kunbo Medical's rich product line in this area [1]

Core Viewpoint - The company, Kangda New Materials (002669.SZ), has announced a strategic acquisition of 51% equity in Zhongke Huami, aiming to enhance its presence in the semiconductor integrated circuit sector and improve profitability through synergies in development strategy, market channels, and technology [1] Group 1: Acquisition Details - The company will acquire the stake for a total of RMB 275 million using its own and raised funds [1] - Following the completion of the transaction, Zhongke Huami will become a subsidiary of the company and will be included in the consolidated financial statements [1] Group 2: Strategic Implications - The acquisition aligns with the company's strategy of integrating "new materials + electronic technology" and aims to expand into the high-quality assets of special integrated circuit design and testing [1] - The transaction is expected to generate new revenue and profit growth points for the company, enhancing its profitability and sustainability [1]